Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Asia Deal Watch: Daiichi Sankyo Licenses Glycotope's Gatipotuzumab ADC

Aug 02 2018

• By Scrip Team

DealWatch_1200x675

Related Content

Cipla Cuts Down In-House Biosimilars Plans

May 26 2017

Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships

May 24 2018

Finance Watch: Early-Stage Firms Gain Deal-Making Insight As Golumbeski Joins VC Ranks

May 22 2018

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

Jul 13 2018

Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C

Jul 05 2018

Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum

Dec 26 2017

China Investment Roundup: Spotlight On Oncology

Oct 31 2017

Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions

Dec 15 2016

Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies

Aug 17 2017

Related Companies

Daiichi Sankyo Co., Ltd.

Glycotope GmbH

Tasly Pharmaceutical Group Co., Ltd.

Mesoblast Limited

Tasly Pharmaceutical Group Co., Ltd.

Tasly Pharmaceutical Group Co., Ltd.

Cipla Limited

WuXi AppTec

Karyopharm Therapeutics

Bristol Myers Squibb Company

I-Mab Co., Ltd

ABL Bio Corp.

MorphoSys AG

Genexine Inc.

Merck & Co., Inc.

NeoImmuneTech, Inc.

Merck & Co., Inc.

AstraZeneca PLC

Additional Topics

Asia Pacific Deals M & A Commercial BioPharmaceutical

More from Focus On Asia

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window